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WALLEYE DERMAL SARCOMA VIRUS ORF C: A POTENTIAL ONCOLYTIC 
THERAPY 
 
Walleye dermal sarcoma virus (WDSV) is a complex retrovirus that causes the 
growth of multifocal, cutaneous tumors in walleye fish (Sander vitreus vitreus). These 
virus-induced tumors spontaneously regress on a seasonal basis. The WDSV genome 
encodes three accessory proteins (rv-cyclin, Orf B, and Orf C) that are necessary for 
regulation of virus expression, tumor formation, and tumor regression. While rv-cyclin 
and B are critical for tumor development, Orf C contributes to the observed seasonal 
tumor regression.  Previous studies have shown that Orf C targets the cell mitochondria 
and induces apoptosis. These studies suggest that Orf C-induced apoptosis leads to the 
observed tumor regression in fish infected with WDSV. To further define the 
mechanism(s) of apoptosis, we generated a recombinant lentivirus (Lenti Orf C) that 
expresses WDSV Orf C. By infecting cells with Lenti Orf C, we showed decreasing cell 
viability in association with increasing virus concentrations.  We also demonstrated Orf C 
expression in mitochondrial, cytosolic, and nuclear cell fractions, with the strongest Orf 
C expression in cell nuclei.  In addition, we identified two pro-apoptotic proteins 
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that associate with Orf C, ANT and Bax, and identified a third protein, AIF, as a potential 
Orf C target.  While significant progress has been made in elucidating the mechanism(s) 
of Orf C-induced apoptosis, further studies are necessary to determine which cellular 
proteins are the primary targets of Orf C.  These apoptosis-inducing Orf C targets may be 



















Cancer is responsible for 13% of human deaths worldwide (American Cancer 
Society, 2007).  It affects people of all ages, with an increasing risk of most cancer types 
as people age.  Based on cancer incidence rates from 2005-2007, 40.7% of men and 
women will develop cancer at some point during their lifetime (Altekruse et al., 2010). 
Given the high incidence of this deadly disease, President Nixon proclaimed a “War on 
Cancer” in the U.S. in 1971.  Since that time the U.S. has invested over $200 billion into 
cancer research (Begley, 2008).  This investment has resulted in a 5% decrease in cancer-
associated mortalities from 1950-2005 (Kolata, 2009).  Given the modest nature of cancer 
decline over the past 50 years, the search for effective cancer therapies continues to be of 
the utmost importance.   
In the quest for an agent to induce cancer cell death, many studies have focused 
on viruses that cause cell death via apoptosis.  Apoptosis is defined as programmed cell 
death, which is an innate cellular response to infection that limits proliferation of viruses 
and intracellular bacteria by killing the infected cells.  However, some clever infectious 
agents have evolved ways to express proteins that induce apoptosis, which for them is 
used as a mechanism of pathogen dispersal and proliferation (Boya et al., 2001).  We can 
potentially use apoptosis-inducing viral pathogens to kill cancer cells by controlling 
which cells these pathogens target for death. 
Under conditions in which cancer cells undergo apoptosis, the term oncolysis is 




cancer cells, and researchers have examined these viruses as potential oncolytic 
treatments.  For example, reoviruses are a useful therapy in treating human lymphoid 
malignancies.  Reoviruses target and kill neoplastic cells with an activated Ras-signaling 
pathway (via mutation of the ras oncogene), but leave non-neoplastic cells unharmed 
(Alain et al., 2002).  A second example of an oncolytic virus is an attenuated herpes-
simplex-virus mutant that induces tumor cell regression in human neural tumors (Kesari 
et al., 1995).  Another virus that may offer similar oncolytic potential is a walleye virus, 
called walleye dermal sarcoma virus (WDSV).  Initial studies show WDSV causes cell 
apoptosis (Nudson et al., 2003).  Further characterization of this walleye virus is 
necessary to determine its potential as an effective oncolytic therapy.  
 
WDSV Background 
Walleye dermal sarcoma virus is a type-C retrovirus (Martineau et al., 1991; 
Martineau et al., 1992) that infects walleye fish (Sander vitreus vitreus) throughout North 
America.  The virus induces skin lesions that range from epidermal hyperplasia to dermal 
sarcoma (Walker, 1969).  Walleye dermal sarcomas (WDS) are grossly identifiable as 
clusters of spherical nodules (2-5 mm) with either a smooth or ulcerated surface.  The 
tumors are found multifocally on any region of the skin, and are generally non-invasive.  
Microscopically the tumors show a defined demarcation from the dermis and a variable 
cellularity. The sarcomas show whorls of fibroblast-like cells with abundant basophilic 




intracellular osteoid material.  Often lymphocytic inflammation is present to varying 
degrees in the dermis adjacent to the tumor (Martineau et al., 1990b).  
Since the initial discovery of walleye dermal sarcoma, much has been discovered 
about its cause and pathogenesis.  The lymphocytic inflammatory response observed in 
dermal sarcomas is most pronounced in fish collected during the spring and summer, with 
minimal inflammation present in those fish collected during the fall (Bowser et al., 1988).  
The inflammatory response does not correlate with the seasonal prevalence of the tumors 
themselves, as the dermal sarcomas are more prevalent in the fall and spring versus 
summer (Bowser et al., 1988).   This difference in seasonal prevalence of tumor growth 
may be correlated with water temperature, although other host and environmental factors 
likely contribute to disease.   Experimental transmission studies demonstrated that 15°C 
was the optimal temperature for tumor growth, suggesting that as the water temperature 
drops in the fall conditions are ideal for tumor development (Bowser et al., 1990).   
To further examine the difference in seasonal prevalence, experimental virus 
transmission was attempted using cell-free inocula from tumors harvested in the spring 
versus fall.  Only the inocula derived from spring tumors produced transmissible tumors 
(Bowser et al., 1996).  Additional analyses found that only the spring tumors harbored 
high levels of virus, while the fall tumors contained little to no virus (Martineau et al., 
1992; Bowser et al., 1996).   
The experimental transmission of WDS to walleye further supports the theory that 
the dermal sarcoma lesion is caused by a virus.  A study by Holzschu et al. (1997b), 




intramuscularly with WDS cell free filtrates.  These transmissibility experiments also 
demonstrated that the tumors formed via virus inoculation were generally non-invasive 
and restricted to the dermis (Marineau et al., 1990a; Holzschu et al., 1997b).   
While nearly all feral observations of these dermal sarcomas have demonstrated a 
benign presentation, experimental infection of young walleye fingerlings show a higher 
prevalence of invasive neoplasms.  One study using 9 week old fingerlings demonstrated 
an occasional locally invasive neoplasm following intramuscular inoculation (Earnest-
Koons et al., 1996).  A second study using slightly younger fingerlings (6-8 weeks) found 
100% of 6-8 week old fingerlings developed invasive tumors when inoculated 
intramuscularly (Bowser et al., 1997).  The formation of this invasive tumor may be 
related to the young age of the walleye at time of initial infection, stressful housing 
conditions, and/or captive diet (Earnest-Koons et al., 1996).  A more recent study also 
found invasive WDS tumor in three adult walleye fish (Bowser et al., 2002), but this 
finding remains rare.   
 One of the most interesting WDS characteristics is that the tumors regress in the 
spring/summer, and this regression can be in part be correlated to an increasing water 
temperature (Bowser and Wooster, 1991; Getchell et al., 2000a).   Once the tumor 
regresses, the walleye fish develop resistance to the virus and have a much lower 
probability of tumor redevelopment (Getchell et al., 2000b; Getchell et al., 2001).  This 
tumor regression occurs via apoptosis (Quackenbush et al., 2001; Nudson et al., 2003; 
Rovnak and Quackenbush, 2010).  Further study of the specific genes causing the tumor 





WDSV molecular structure 
It was confirmed in 1991 that a type-C retrovirus was present in walleye dermal 
sarcomas using molecular techniques and likely the etiological agent (Martineau et al., 
1991; Martineau et al., 1992).  This proposed etiology was further supported by the 
detection of abundant viral transcripts within the neoplastic tumor cells (Poulet et al., 
1995).  Retroviruses can play a role in tumorigenesis via their ability to convert RNA 
genome to double-stranded DNA that can integrate into the host genome and convert 
proto-oncogenes into oncogenes via retroviral transduction (Bowser and Casey, 1993).   
WDSV is also unique in that it contains high levels of un-integrated viral DNA, a 
rarity among oncovirus-induced tumors (Bowser and Casey, 1993; Martineau, 1992).  
High virus levels are found in tissues from regressing spring tumors.  The regressing 
spring tumors yielded 10-50 copies of viral DNA per cell.  In contrast, less than one copy 
of viral DNA per cell was isolated from the developing fall tumors (Bowser et al., 1996).  
The regressing spring tumors contained the full length genomic RNA, while it was 
undetectable in the developing fall tumors (Bowser et al., 1996; Martineau et al., 1991; 
Martineau et al., 1992).  In addition, the fall tumors only express two spliced transcripts, 
while the spring tumors express these two spliced transcripts plus spliced env and the full 
length genomic RNA (Quackenbush et al., 1997).  There is also a significant quantitative 
difference in the expression of these subgenomic transcripts between the two seasons, 
with the viral mRNA from spring tumors demonstrating levels up to 100x greater than 




The entire nucleotide sequence of a DNA clone of walleye dermal sarcoma virus 
has been determined and shows several distinguishing features within its 12,708 bp 
sequence (Holzschu et al., 1995; Holzschu et al., 1997a).  Long terminal repeats (LTRs) 
measuring 590 bp bracket each end.  The LTRs contain a U3 region of 440 bp, a 77 bp R 
region and a 73 bp U5 region, with the start site of transcription located at the junction 
between the U3 and R regions.  Also present in the LTR are a consensus polyadenylation 
sequence and TATA box.   Another unique molecular characteristic of WDSV is that in 
addition to encoding the open reading frames (ORFs) present in all retroviruses, gag, pol, 
and env, it also contains three accessory genes orf A, orf B, and orf C.  Orf A and Orf B 
are located between the env gene and the 3’ LTR, while Orf C is found in the leader 
region between the gag gene and the 5’ LTR (Holzschu et al., 1995; Holzschu et al., 
1997a).   
  
(Quackenbush et al., 1997) 
 
WDSV Orf A encodes the protein rv-cyclin that is specifically expressed at the 
time of tumor development (Rovnak et al., 2001).  This finding suggests that rv-cyclin 
plays a role in WDS induction.  It has additionally been shown that rv-cyclin localizes to 




mRNA transcription (Rovnak et al., 2001).  Transcription has been shown to be affected 
via the direct interaction between rv-cyclin and TAF9 (Rovnak and Quackenbush, 2006), 
which interferes with NF-ĸβ and downregulates NF-ĸβ-dependent transcription 
(Quackenbush et al., 2009), potentially contributing to tumorigenesis. 
Additional evidence suggesting a role of rv-cyclin in tumor development is that 
rv-cyclin affects cell growth (LaPierre et al., 1998; Lairmore et al., 2000, Brewster et al., 
2011).  WDSV rv-cyclin enhances host gene expression and proliferation of mammalian 
cells and is able to rescue cyclin-deficient yeast from growth arrest (LaPierre et al., 1998; 
Brewster et al., 2011).  Further support exists in the finding that rv-cyclin induces a 
squamous epithelial hyperplasia in transgenic mice (Lairmore et al., 2000).   
Orf B localizes to the cell cytoplasm (Rovnak et al., 2007).  In this location Orf B 
directly interacts with the receptor for activated C kinase (RACK1) and activates protein 
kinase C (PKC) (Daniels et al., 2008). PKC serves a wide variety of functions, ranging 
from cell proliferation to apoptosis (Nakashima, 2002).  In Orf B expressing cells, the 
activation of PKC appears to convey a cellular ability to survive, and even proliferate, in 
serum-deprived conditions (Daniels et al., 2008).   Both rv-cyclin and Orf B are 
expressed in the developing fall tumors, indicating these genes may play a role in tumor 
development (Quackenbush et al., 2001).   
Orf C is encoded by the full-length genomic RNA, which is expressed at very 
high levels during tumor regression (Quackenbush et al., 1997; Quackenbush et al., 
2001).  Orf C localizes to the cell mitochondria and causes an alteration in mitochondrial 




expressing Orf C exhibit a distinctly different morphology and loss of membrane 
integrity, further evidence that Orf C is associated with induction of apoptosis.  
Additionally, cells transfected with an Orf C expression construct and stained with 
Annexin V (an apoptosis-indicator) show increasing levels of apoptosis over 48 hours 
when compared to rv-cyclin expressing cells (Nudson et al., 2003).  The apoptotic ability 
of Orf C supports the theory that Orf C expression from the full length genome plays a 
significant role in tumor regression via an apoptotic pathway. 
 
Orf C - mechanisms of apoptosis 
Mitochondria have been shown to play a critical role in the process of apoptosis 
via the extrinsic or intrinsic pathways.  When the extrinsic pathway is initiated, apoptosis 
occurs via death receptors expressed at the cell surface that activate caspases which alter 
the mitochondrial membrane potential (MMP), while the intrinsic pathway initiates 
intracellular death signals that target the mitochondria directly and alter the MMP prior to 
caspase activation (Boya et al., 2004; Brenner et al., 2000; Everett et al., 2001; Green et 
al., 1998; Kroemer et al., 1998; Reed et al., 2000).  
Both extrinsic and intrinsic apoptosis pathways generally either involve proteins 
from the caspase family and/or the Bcl-2 family.  During mitochondrial targeted 
apoptosis proteins from the inter-membrane space between the inner and outer 
mitochondrial membranes, such as cytochrome c, leak into the cell cytosol.  These leaked 
proteins will activate procaspase-9, which in turn activates the pro-apoptotic protein, 




apoptosis-inducing factor, AIF (Everett et al., 2001; Martinou et al., 2001; Zamzami et 
al., 2001).  The pro-apoptotic proteins in the Bcl-2 family include Bax, Bak, and Bid.  
Activation of these Bcl-2 proteins acts as a junction between the extrinsic and intrinsic 
pathways that amplifies the apoptosis process (Everett et al., 2001; Heibein et al., 2000). 
In addition to the pro-apoptotic Bcl-2 proteins and caspases, other pro-apoptotic 
stimulators include non-proteinaceous factors such as fatty acids or nitric oxide and 
transcription factors such as p53 and NGF1β (Boya et al., 2001).  These apoptosis 
initiating signals can target a wide variety of mitochondrial membrane receptors 
including lipid rafts, cardiolipin, adenine nucleotide translocase (ANT), and voltage-
dependent anion channel (VDAC) (Boya et al., 2001).  As these membrane receptors are 
targeted, there is a corresponding loss of electrochemical potential across the inner 
mitochondrial membrane due to the opening of the permeability transition (PT) pore 
(Zamzami et al., 2001).  The PT pore is comprised of the voltage-dependent anion carrier 
(VDAC) in the outer mitochondrial membrane, adenine nucleotide translocase (ANT) in 
the inner mitochondrial membrane, and cyclophilin D (CPD) which is closely associated 
with ANT (Crompton, 1999).   Thus far, all the virus-associated pro-apoptotic proteins 
have amphipathic α-helices with pore-forming properties (Boya et al., 2004).  It is likely 
that WDSV Orf C induces apoptosis via one of these pro-apoptotic pathways, ultimately 
leading to the observed seasonal tumor regression.    
 Given the ability of WDSV Orf C to induce apoptosis, the goal of this study is to 
determine the mechanism(s) of Orf C-induced apoptosis and use this oncolytic property 




by which WDSV Orf C induces apoptosis, we can gain information necessary to develop 
an effective oncolytic therapy. 
 
Specific AIMS 
 WDSV is known to express the viral accessory protein, Orf C, at the time of 
tumor regression.  Previous work has demonstrated that Orf C targets cell mitochondria 
and affects the mitochondrial membrane potential (Nudson et al., 2003).  It has also been 
shown that Orf C expressing cells undergo apoptosis (Nudson et al., 2003).  Based on 
these previous observations we hypothesize that Orf C interacts with the permeability 
transition pore complex (PTPC) to initiate apoptosis.  We have outlined several AIMS 
and associated goals to test this hypothesis. 
 
AIM 1.  To construct a recombinant lentivirus expressing WDSV Orf C and assess its 
affect on cell growth. 
We used the pLVX-Puro Vector (Clontech®), a lentiviral expression vector based 
on human immunodeficiency virus-1, to express WDSV Orf C.  To evaluate the 
apoptosis potential of our recombinant Orf C-expressing lentivirus we used an in vitro 
assay to screen various cell lines for use in our in vitro experiments. 
AIM 2.  To determine the subcellular localization of the lentivirus expressed Orf C 
We assessed Orf C expression in mitochondrial, nuclear, and cytosolic cell 




AIM 3.  To determine the mechanism of Orf C-induced apoptosis. 
Caspase activation in Orf C-expressing cells 
We examined several caspases (3, 6, 9, and 12) to determine if Orf C induces 
apoptosis via a caspase-dependent or caspase-independent pathway, and to show which 
pathway may be activated.  Specifically, we looked for the activated cleaved caspases in 
association with Orf C expression.    
Identification of Orf C interacting proteins 
We analyzed transition pore complex proteins VDAC (voltage-dependent anion 
channel) and ANT (adenine nucleotide translocase) for potential interaction with Orf C.  
We also conducted in vitro experiments evaluating the potential activation of several pro-
apoptotic proteins (Bcl-2, Bax, AIF). 
AIM 4.  To assess Orf C’s potential as an oncolytic therapy. 
Once the mechanism of Orf C-induced apoptosis has been determined, we 
propose an experiment analyzing the potential in vivo use of Orf C as an oncolytic 
therapy.   
 
Materials and Methods 
Recombinant lentivirus expression system 
The pLVX-Puro Vector (Clontech®) is a lentiviral expression vector based on 




interest, WDSV Orf C, as this expression system is more efficient than standard 
transfections.  We also used the empty lentiviral vector as an experimental control.  Gene 
expression with this system is driven by a cytomegalovirus (CMV) promoter located 
upstream from the multiple cloning site (MCS).  The pLVX-Puro Vector is 8102 base 
pairs and contains both a puromycin resistance gene, for selection of stable transductants 
in mammalian cells, and an ampicillin resistance gene for propagation and selection in 
bacteria. 
The insert, Orf C, was excised from the pKH3-Orf C expression construct 
(Nudson et al., 2003). Two µg were digested with SalI and ClaI (NEBuffer 2 (New 
England BioLabs, Inc.; 50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 1 mM 
Dithiothreitol, pH 7.9), 1x BSA (bovine serum albumin)) and incubated at 37 °C 
overnight.  The pLVX-Puro vector (two µg) was digested with compatible enzymes XhoI 
and BstBI (NEBuffer 4 (New England BioLabs, Inc., 50 mM potassium acetate, 20 mM 
Tris-acetate, 10 mM magnesium acetate, 1 mM Dithiothreitol, pH 7.9), 1x BSA) and 
incubated at 37°C overnight.   
Digests were separated on a 1% agarose TAE (0.04 M Tris-acetate, and 1 mM 
ethylenediaminetetraacetic acid (EDTA) and glacial acetic acid) gel run at 70 volts for 90 
minutes.  The appropriate bands were cut out: 357 bp for Orf C and 8.1 kb for pLVX-
Puro vector.  DNA was extracted from the gel with the Qiagen® QIAquick Gel 
Extraction Kit.  Gel slices were combined with three times the volume of QG buffer 
(Qiagen® solubilization and binding buffer) and incubated at 50°C for ten minutes to 
dissolve agarose.  Mixture was applied to the QIAquick® spin column.  The nucleic acids 




were rinsed away with 750 µL of PE wash (Qiagen® wash buffer, 10 mM Tris-HCl pH 
7.5, 80% ethanol) and column was spun again for one minute.  Excess alcohol was 
removed with a final 90 second spin.  DNA was eluted with 50 µL of EB buffer 
(Qiagen® elution buffer; 10 mM Tris-Cl, pH 8.5) and the column was spun for one 
minute.  Purified DNA was quantitated on an ethidium bromide agarose gel by 
comparing to the NEB 1 kb ladder as a standard.   
Ligation was performed with 50 ng of digested pLVX puro vector plus 7.5 ng Orf 
C insert (3:1 molar ratio) with NEB T4 ligase (New England BioLabs, Inc.,) in 1x ligase 
buffer (50 mM Tris-HCl, 10 mM MgCl2, 1 mM ATP, 10 mM Dithiothreitol, pH 7.5) in 
15 µL and incubated overnight at 4°C.  JM109 E.coli chemically competent cells were 
used for the transformation.  Five µL of the ligation was added to 100 µL of JM109 cells 
and placed on ice for 30 minutes.  The cells and ligation were next heated to 42°C for 45 
seconds, and then placed on ice for two minutes.  Super optimal broth (SOB) (0.5 mL) 
(Bacto-tryptone 2%, yeast extract 0.5%, NaCl 0.005%, KCl 2.5 mM, 10mM MgCl2 pH 
7.0) was added to the tube and shaken at 37°C for 90 minutes.  Next the mixture was 
spread on LB (Lysogeny Broth) ampicillin plates (Tryptone 1%, yeast extract 0.5%, NaCl 
1%, Agar 1.5%, 0.1 mg/mL ampicillin) and incubated overnight at 37°C.  One colony 
was observed the following day.  The single colony was harvested and placed in 100 mL 
LB-amp overnight at 37°C with shaking (250 rpm).   
Following overnight LB-amp growth the plasmid was isolated with Promega’s 
Pure Yield™ Midiprep System kit.  The cultures were centrifuged (Sorvall® RC6 with 
S534 rotor at 9,000 x g for ten minutes) and the resulting pellet was resuspended in three 




RNase A) by vortexing.  Next, three mL cell lysis buffer (0.2 M NaOH, 1% SDS) was 
added and maintained at room temperature for three minutes, followed by the addition of 
five mL neutralization buffer (4.09 M guanidine hydrochloride (pH 4.8), 759 mM 
potassium acetate, 2.12 M glacial acetic acid) to precipitate genomic DNA and protein 
structure.  The tubes were then incubated at room temperature for three minutes. 
The precipitated bacterial lysate was clarified by pouring into a clearing column 
and allowed to incubate three minutes before vacuum pressure was applied to the column.  
The DNA containing flow-through passed onto a DNA binding column and the vacuum 
was slowly released.  Next, the membrane-bound DNA was washed by adding five mL 
endotoxin removal wash (Promega PureYield™ Plasmid Midiprep System) and vacuum 
pressure was reapplied.  Column wash (20 mL) (162.8 mM potassium acetate, 22.6 mM 
Tris-HCl (pH 7.5), 0.109 mM EDTA (pH 8.0) with 95% ethanol added before use to a 
final concentration of 60% ethanol, 60 mM potassium acetate, 8.3 mM Tris-HCl, and 
0.04 EDTA) was added and vacuum pressure was again applied.  The membrane was 
dried by applying vacuum for 30 seconds.  The DNA was eluted from the membrane with 
600 µL of nuclease-free water.  The Eppendorf BioPhotometer 6131 was used to 
determine the concentration of purified DNA (546.4 µg/mL) by absorbance at 260 nm. 
Next, restriction digests were performed to confirm the presence of Orf C.  Since 
compatible enzymes were used for initial cloning (SalI-XhoI and BstBI-ClaI) they could 
not be used to recut for confirmation of appropriate insert.  We instead used EcoRI and 
KpnI digests to screen the clone for insertion and correct orientation and separated the 
digest on a 2% agarose TAE gel at 100 volts.  The resulting banding patterns matched 




200 bp fragment with EcoRI and correct orientation was confirmed with a 100 bp 
fragment with KpnI.  Sequence was further confirmed via DNA sequencing.   
 
Lenti Orf C virus production.  
The Lenti-X™ HT Packaging System, along with Lenti-X™ 293T cell line, was 
originally used for the production of both Lenti Orf C and Lenti empty vector viruses, 
following the protocol from Clontech Laboratories, Inc. entitled, “Protocol: Lentiphos™ 
HT Protocol.”  We followed the same procedure at a later date using the Lenti-X™ HT 
Ecotropic Packaging system to produce ecotropic Lenti Orf C and ecotropic Lenti empty 
vector viruses (ecotropic envelope glycoprotein (gp70)).  Both protocols involved adding 
4 x 10
6
 Lenti-X™ 293 T cells in 10 mL of Dulbecco’s modified Eagle medium 
(DMEM/High Glucose, Hyclone® Thermoscientific; 4 mM L-glutamine, 4500 mg/L 
glucose, -sodium pyruvate) with 10% fetal bovine serum (FBS) (Benchmark™, Gemini 
Bio-Products) to 100 mm tissue culture plates 24 hours prior to transfection.  Plates were 
incubated at 37°C overnight (24 hours) in 5% CO2.  Lenti Orf C plasmid DNA (three µg) 
was added to 15 µL of Lenti-X™ HT Packaging Mix or Lenti-X™ HT Ecotropic 
Packaging system and 423 µL sterile H2O into 12 x 75 mm polystyrene tubes.  
Lentiphos1 solution (62 µL) was added to the diluted Lenti Orf C plasmid DNA and 
vortexed thoroughly.  While vortexing the DNA/Lentiphos1 solution, Lentiphos2 (500 
µL) was added dropwise into the tube.  The mixture was incubated at room temperature 
for ten minutes to allow DNA precipitate to form.  The solution was then gently vortexed 




were incubated overnight at 37°C.  Following the 24 hour incubation period, the 
transfection medium was aspirated and replaced with 10 mL of fresh cell culture medium 
and plates were incubated an additional 48 hours at 37°C.  Following this 48 hour 
incubation, supernatants were collected, centrifuged at 500 x g for ten minutes to remove 
cellular debris, aliquoted, and stored at -80°C.   
Following virus production, virus titrations were performed using HeLa cells 
infected with 10-fold dilutions of Lenti Orf C or Lenti empty vector virus in DMEM with 
10% FBS.  Polybrene (8 µg/mL) (hexadimethrine bromide) was added to the cell culture 
media to enhance infectivity.  Twenty-four hours post transfection, virus and media were 
aspirated and puromycin (5 µg/mL) selection began.  Antibiotic resistant colonies were 
allowed to grow for 10-14 days with fresh media changes occurring every two or three 
days.  All media was then aspirated and cell colonies were stained with 1% crystal violet 
solution in EtOH and enumerated.   
Due to low virus titers, FuGene® 6 Transfection Reagent (Roche) was also used 
to grow virus in an attempt to achieve higher viral titers.  For these transfections, we 
combined 835 µL of Opti-MEM® (Invitrogen™) with 25 µL FuGene® (Roche) and 
incubated at room temperature for five minutes.  We then added a DNA mixture 
containing Lenti Orf C (3.4 µg), and the packaging plasmids pLP/VSV-G (1.2 µg) 
(Vesicular Stomatitis Virus G glycoprotein; 1 µg/mL in TE buffer (Tris 10 mM, EDTA 1 
mM)), pLp1 (encodes gag/pol; 1 µg/mL in TE buffer) (3.7 µg), and pLp2 (encodes rev; 1 
µg/mL in TE buffer) (1.7 µg) to the Opti-MEM®/FuGene® solution and incubated 
another 15 minutes.  The entire mixture was added to the 293T cells/media and incubated 




was harvested, centrifuged at 500 x g for 15 minutes to remove cellular debris, and stored 
at -80°C.  Due to a failed lot of FuGene® 6 Transfection Reagent (Roche), we substituted 
an improved FuGene® HD Transfection Reagent (Roche) for virus production later in the 
study.  
Ultracentrifugation was used to further increase our virus concentrations.  Viral 
supernatants were added to Ultra-Clear™ Beckman centrifuge tubes (25 x 89 mm) and 
balanced centrifuge tubes were placed in a cooled SW-28 swinging bucket rotor.  Tubes 
were centrifuged at 16,500 rpm (30,500 x g) for 90 minutes and the resulting viral pellet 
was resuspended in 1/100
th
 of original volume of filtered cold TNE solution (10 mM Tris, 
0.1 M NaCl, 1 mM Na2EDTA, adjust to pH of 7.5 with HCl) and virus was stored at -
80°C. 
 
In vitro assessment of the effect of Orf C on cell growth    
To assess the effect of Orf C expression on cell growth, we performed cell 
viability assays using a variety of cell types.  We analyzed the effect of Orf C on the 
growth of 4T1, MCA-205, and NIH-3T3 cells in order to establish which cell line would 
function best as a model of Orf C-induced apoptosis.  In 96-well tissue culture plates, 
2500 cells were plated per well, with 42 wells of each cell type and 12 wells left blank to 
measure background absorbance.  Experimental samples consisted of 6 wells each of 
uninfected cells, Lenti empty vector infected cells at multiplicity of infection (MOI) of 5, 
10, and 20, and cells infected with Lenti Orf C at the same virus concentrations (results 




triplicate in order to assess cell viability at three different time points: 24, 48, and 72 
hours post-infection.  The virus was added to the wells along with media (DMEM with 
10% FBS) plus polybrene (8 µg/mL) in a total volume of 100 µL per well.  The tissue 
culture plates were incubated overnight at 37°C.   
Twenty-four hours post-infection the first set of 96 well plates were analyzed for 
cell viability using CellTiter96® Aqueous One Solution Cell Proliferation Assay (MTS) 
(Promega™).  The media from each individual well was aspirated and replaced with 100 
µL of fresh DMEM with 10% FBS.  We then added 20 µL of the CellTiter96® Aqueous 
One Solution Reagent to the cultured cells.  The plates were incubated for 1-3 hours at 
37°C in a humidified chamber in 5% CO2.  The resulting absorbance was then recorded 
at 490 nm using the Beckman Coulter™ LD 400 plate reader. 
The virus and media from the remaining tissue culture plates (48- and 72-hour 
incubation periods) were aspirated and 200 µL of fresh media (DMEM with 10% FBS) 
was added to each well.  The same cell viability assay procedure was used for these tissue 
culture plates at 48 and 72 hours post-infection.   
This cell viability experiment was repeated one time using the CellTiter-Blue® 
Cell Viability Assay (Promega™).  Cells (2 x 10
3
 4T1 and NIH-3T3 cells) were plated in 
a 96-well opaque black plate suitable for cell culture with 200 µL of DMEM with 10% 
FBS.  Cells were infected with Lenti Orf C or Lenti empty vector virus (VSVG) at a MOI 
of 0, 1, 5, or 10 (n=3, due to virus volume constraints) and incubated for 48 hours at 
37°C.  CellTiter-Blue® Reagent (20 µL/well) was added and plate was shaken for ten 




for ten seconds and resulting absorbance was recorded at 560/590 nm using a fluorescent 
plate reader. 
Statistical analyses were performed using a one-sided two-sample student’s t-test, 
with significance set at p-value < 0.05. 
 
Subcellular localization of the lentivirus expressed Orf C 
To demonstrate subcellular localization of Orf C, HeLa cells were transfected 
with pKH3 or pKH3-Orf C.  For these transfections, we combined 500 µL of Opti-
MEM® (Invitrogen™) with 40 µL FuGene® HD (Roche) and incubated at room 
temperature for five minutes.  We then added 10 µg of DNA (pKH3 or pKH3-OrfC) to 
the Opti-MEM®/FuGene® mixture and incubated at room temperature for 15 minutes.  
The complete mixture was gradually dripped onto a 100 mm tissue culture plate of HeLa 
cells (3 x 10
6
 cells) that had been plated the previous day, and the transfected cells were 
incubated at 37°C with 10 mL of DMEM with 10% FBS for a total of 48 hours.   
At 48 hours post-transfection all media was aspirated, cells were rinsed with 
Phosphate buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 
mM KH2PO4, adjust to pH 7.4), and trypsin (0.05% plus EDTA in Hanks Balanced Salt 
Solution (HBSS); 0.137 M NaCl, 5.4 mM KCl, 0.25 mM Na2HPO4, 0.44 mM 
KH2PO4,1.3 mM CaCl2, 1.0 mM MgSO4, 4.2 mM NaHCO3) was added to the cells.  
Cells were harvested and transferred to a 50 mL conical tube, and centrifuged at 500 x g 
for five minutes.  Cells were then washed twice with 10 mL of PBS and re-centrifuged at 




Mitochondrial, nuclear, and cytosolic cells fractions were then isolated following 
the MitoProfile® benchtop mitochondrial isolation kit for cultured cells (Mitosciences®).  
Following cell collection and wash, the cells were placed at -80°C to freeze cells, and 
then thawed on ice to weaken the cell membranes.  The cells were then resuspended in 
five mg/mL Reagent A with added proteinase inhibitor (Sigma) (ten µL/mL) and PMSF 
(phenylmethanesulfonylfluoride) (two µL/mL), and incubated on ice for ten minutes.  
The cells were transferred to a pre-cooled Dounce homogenizer and homogenized using 
20 strokes with a B pestle.  The homogenate was transferred to a centrifuge tube and 
centrifuged at 1,000 x g for ten minutes at 4°C.  The resulting supernatant was saved as 
supernatant #1.   
The resulting pellet was resuspended in Reagent B with added proteinase inhibitor 
and PMSF with the same volume used as Reagent A.  The same rupturing and spin steps 
were repeated as with Reagent A.  The pellet resulting from this second spin cycle 
constituted the nuclear cell fraction.  Nuclear cell fractions were gently washed twice 
with Reagent B by resuspending the nuclear pellet in 1 mL of buffer, centrifuging at 1500 
x g for three minutes, and then adding Dignam C extraction buffer (20 mM HEPES (pH 
7.9), 25% (v/v) glycerol, 0.42 M NaCl, 1.5 M MgCl2, 0.2 mM EDTA, 0.5 mM PMSF, 
0.5 mM DTT) at two volumes buffer: one volume nuclear pellet.  The pellet was rotated 
overnight at 4°C and samples were then frozen at -80°C.   
The supernatant (supernatant #2) was combined with supernatant #1, mixed 
thoroughly, and centrifuged at 12,000 x g for 15 minutes at 4°C.  The resulting 
supernatant from this final centrifuge was saved as the cytosolic cell fraction.  The 




cell pellet) of Chaps® Cell Extract Buffer (Cell Signaling Technology®) (0.1% Chaps, 
50 mM Pipes/HCl (pH 6.5), 2 mM EDTA, 20 µg/mL Leupeptin, 10 µg/m: Pepstatin A 10 
µg/mL Aprotinin, 5mM DTT).  Resuspended mitochondria were frozen at -80°C and 
thawed twice on ice, followed by centrifugation at 14,000 rpm at 4°C for five minutes to 
lyse mitochondria.  Samples were frozen at -80°C. 
To determine the subcellular localization of Orf C following infection, four 
different cell types were infected with either Lenti Orf C, Lenti empty vector, or 
remained un-infected as a control.  The cell types used were: 4T1 cells, a mouse 
mammary tumor cell line; HeLa cells; NIH-3T3 cells, a mouse fibroblast line; and MCA-
205 cells, a mouse sarcoma cell line.  The 4T1 and MCA-205 cells were of most interest 
as a potential cancer cell line in which we could demonstrate apoptosis. 
Using 6-well tissue culture plates, 3 wells of each cell line were plated at a 
concentration of 2 x 10
5
 cells/well.  One well was left uninfected, one well was infected 
with Lenti empty vector virus, and one well was infected with Lenti Orf C virus.  The 
virus concentration used for each experiment varied as indicated in the results section.  
The total volume of virus, media (DMEM with 10% FBS), and polybrene (8 µg/mL) was 
1 mL/well.  The tissue culture plates were incubated overnight at 37°C.  At 24 hours 
post-infection, trypsin was added to the cells and each well was split into two 100 mm 
tissue culture plates.  DMEM with 10% FBS was added to each plate (ten mL) and 
incubated for 48 additional hours.  Cells were harvested by trypsinizing cells, transferring 
cells to a 50 mL conical tube, and centrifuging at 500 x g for five minutes.  Cells were 
rinsed with PBS and re-centrifuged at 500 x g for five minutes (x2).  Mitochondrial, 




benchtop mitochondrial isolation kit for cultured cells (Mitosciences®), as described 
above.   
Protein concentrations for the various cell fractions were determined using a 
Micro BCA™ protein assay kit (Thermoscientific®), microplate procedure.  Micro BCA 
Working Reagent (WR) was prepared by mixing 25 parts Micro BCA Reagent MA, 24 
parts Micro BCA Reagent MB, and one part Reagent MC.  We added 150 µL of WR to a 
96 well plate plus 150 µL of the diluted standards or samples (148 µL millQ H2O plus 
two µL sample or standard).  The plate was incubated at 37°C for two hours, cooled to 
room temperature, and the absorbance was measured at 562 nm on a Beckman Coulter™ 
LD 400 plate reader.   
Fifteen µg of each sample was run on a 12-well, 12% acrylamide gel with 200 mL 
MES buffer (2-(N-morpholino) ethanesulfonic acid) plus 0.5 mL NuPAGE® antioxidant 
at 200 V constant for 50 minutes.  Proteins were transferred to an Immobilon™ transfer 
membrane (Millipore™) and run at 150 mAmps constant for two hours.  The membrane 
was rinsed with Tris-buffered saline (TBS) buffer (25 mM Tris) for five minutes and 
placed in blotto (a milk diluents/blocking solution – 5% Carnation® instant non-fat dry 
milk, 10% 10x PBS, 0.0025% Tween 20, in TBS wash) for 30 minutes followed by three 
consecutive washings in TBS buffer for five minutes each.  The primary antibody (XHA 
12CA5, 1:1000) was added to the membrane and incubated at 4°C overnight with 
rocking.  The following day the membrane was rinsed with TBS buffer three times for 
five minutes each and the secondary antibody (G x M IgG HRP, 3:5000) was applied.  




temperature with rocking, rinsed again with TBS buffer (three times, five minutes each), 
and developed with TMB western blot kit (KPL™).  
TMB Peroxidase Substrate (625 µL), Peroxidase Substrate Solution B (625 µL), 
and TMB Membrane Enhancer (125 µL) were mixed in a 5:5:1 ratio.  This solution was 
placed on the rinsed membrane for one hour with a clear plastic sheet on top to prevent 
solution evaporation.  The developed membrane was then scanned (Visoneer® 
OneTouch™ 9400) and the image adjusted with Adobe Photoshop® CS (Version 8.0, 
2003). 
 
Mechanisms of Orf C-induced apoptosis 
Caspase activation in Orf C-expressing cells.  Using a 6-well tissue culture plate, 2 x 10
5
 
cells from both the 4T1 and NIH-3T3 lines were plated in three wells each.  For each cell 
line one well was uninfected, one well was infected with Lenti empty vector virus and 
one was infected with Lenti Orf C virus at a MOI of five to ten.  Virus was added to 
media (DMEM with 10% FBS) plus polybrene (8 µg/mL) to a total volume of 1 mL/well.  
Twenty-four hours post-infection the cells were split into a 100 mm tissue culture plate 
and incubated an additional 24 hours.  Next, the cells were harvested using trypsin and 
ten mL DMEM with 10% FBS was added.  The cell containing solution was centrifuged 
at 500 x g for five minutes.  The resulting cellular pellet was rinsed with 10 mL PBS 
followed by centrifugation at 500 x g for five minutes (x2).   
All PBS was aspirated from the cellular pellet and cells were resuspended in 




1 mM EDTA, 1 mM EGTA (ethylene glycol tetraacetic acid), 0.2 mM sodium ortho-
vanadate, 0.2 mM PMSF, 0.5% Nonidet NP-40 (octyl phenolypolyethoxylethanol)) and 
incubated at 4°C with rotation overnight.  In a duplicate experiment the same protocol 
was used but Chaps® Cell Extract buffer (1 volume buffer:1 volume cell pellet) (Cell 
Signaling Technology®, #9852) (50 mM Pipes/HCl (pH 6.5) 2 mM EDTA, 0.1% Chaps, 
20 µg/mL Leupeptin, 10 µg/mL Pepstatin A, 10 µg/mL Aprotinin, with DTT 
(Dithiothreitol) added to 5 mM) was used in place of the IP buffer used in the original 
experiment.  Cells were centrifuged at 14,000 rpm for ten minutes and the supernatant 
was collected.  A Micro BCA™ protein assay was performed to determine the protein 
concentrations.  Fifteen µg of protein was loaded from each sample onto a Nu-PAGE® 
Bis-Tris 12% acrylamide gel (10 well) and run at 200 V constant for 50 minutes.  
Proteins were transferred to an Immobilon™ transfer membrane (Millipore™) and run at 
150 mAmps constant for two hours.  The membrane was rinsed with TBS wash for five 
minutes and incubated in blotto at room temperature for one hour.  
Following incubation in blotto and three subsequent washes (5 minutes each) with 
TBS buffer, a variety of primary antibodies for caspase detection were applied using the 
Apoptosis Antibody Sampler Kit (Mouse Specific) from Cell Signaling Technologies® 
(#9930).  The primary antibodies used included: caspase-3, cleaved caspase-3 (Asp175) 
(5A1E) Rabbit mAb, caspase-12, caspase-6, cleaved caspase-6 (Asp162), caspase-9, 
cleaved caspase-9 (Asp353), and cleaved-PARP (Poly(ADP-ribose)polymerase) 
(Asp214).  The primary antibodies were diluted to 1:1000 in primary antibody dilution 
buffer (0.5% BSA, 1% 10x TBS, and 90% MilliQ H2O; add 100% Tween 20).  The 




linked (diluted 1:2000 in primary antibody dilution buffer).  The primary antibody was 
incubated with the membrane overnight at 4°C with gentle rocking.  Following three 
washes with TBS buffer, the secondary antibody was applied and incubated at room 
temperature for one hour.  The membranes were then developed with TMB western blot 
kit (KPL™) as previously described. 
 
Identification of Orf C interacting proteins.  Adenine nucleotide translocase (ANT), 
voltage-dependent anion channel (VDAC), Bcl-2 (pro-apoptotic protein), and Bax (pro-
apoptotic protein of Bcl-2 family) were analyzed for interaction with Orf C via 
immunoprecipitation.  Mitochondrial lysates were prepared using the MitoProfile® 
benchtop mitochondrial isolation kit for cultured cells (Mitosciences®) as previously 
described by transfecting HeLa cells with pKH3-Orf C plasmid and resuspending the 
pellet in RIPA buffer (Radioimmunoprecipitation assay buffer ; 150 mM NaCl, 1 % NP-
40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris (pH 8.0), with proteinase 
inhibitors - 10 µL/mL) (200 µL).  Samples were incubated at 4°C for one hour with 
rotation.  The cell suspension was centrifuged at 14,000 rpm for 15 minutes at 4°C and 
the supernatant was placed in a new microcentrifuge tube and placed on ice.  Protein 
concentrations were determined using the previously described Micro BCA™ protein 
assay kit (Thermoscientific®). 
Protein G-Sepharose™ (GE Healthcare) (50 µL) was added to 500 µg protein.  IP 
buffer was added to bring final volume to one mL and microcentrifuge tube was rotated 




supernatant was transferred to a new microcentrifuge tube.  Mouse anti-ANT mAb 
(Mitosciences®, 10 µg/ml) was added and each tube was rotated for 90 minutes at 4°C.  
Protein G-Sepharose™ (30 µL) was added to each tube and incubated overnight at 4°C 
with rotation.   
The following day the tubes were pulse-centrifuged (14,000 rpm) for ten seconds, 
tubes were rotated and pulse-centrifuged (14,000 rpm) again.  Supernatant was saved as 
the unbound fraction from the immunoprecipitation.  RIPA buffer (one mL) was added to 
the pellet and suspension was rotated for 20 minutes at 4°C.  Pulse centrifugation was 
repeated (ten seconds).  RIPA buffer (one mL) wash was performed two times with two 
20 minute rotations at 4°C, followed by pulse centrifugation as described above repeated 
twice.  Supernatant was carefully removed.  Samples were pelleted by centrifugation to 
remove the last traces of supernatant.   
NuPage® SDS-PAGE loading buffer (20 µL) (Invitrogen™) was added to pellets 
and samples were heated at 95°C for three minutes.  Beads were pelleted by 
centrifugation (14,000 rpm for one minute) and supernatants were collected and loaded 
onto a Nu-PAGE® Bis-Tris 12% acrylamide gel with MES buffer and 0.5 mL Nu-
PAGE® antioxidant, and subjected to electrophoresis at 200 V for 50 minutes.  Proteins 
were then transferred onto an Immobilon™ transfer membrane (Millipore™) as 
described above.  Membranes were blocked with 1% serum albumin (BSA) (used 
specifically for ANT antibody) and incubated membrane for 30 minutes at room 




We next added anti-HA antibody (12CA5, 1:1000) diluted in 1% BSA and 
incubated membrane at 4°C overnight.  Membrane was washed with western wash buffer 
three times for ten minutes each and incubated with secondary antibody (Anti-mouse IgG 
peroxidase, 1:2000, diluted in 1% BSA) for one hour at room temperature.  Following 
this incubation period, the membrane was washed with western wash buffer three times 
for ten minutes each and developed in TMB substrate (KPL™) as previously described. 
Bax – Orf-C interaction was investigated by transfecting HeLa cells with pKH3-
Orf C and performing mitochondrial isolation followed by immunoprecipitation as 
described above, with the exception that Bax antibody (Cell Signaling Technology™, 
1:1000) was used and the membrane was blocked using blotto instead of the 1% BSA 
solution.  HA-tagged Orf C was again detected with anti-HA antibody (12CA5, 1:1000).   
AIF (Apoptosis-inducing factor) antibody (Cell Signaling Technology®, #4642) 
was used to identify interactions between Orf C and AIF.  NIH-3T3 and MCA-205 cell 
lines (2 x 10
6
 cells in 100 mm tissue culture plates) were infected with either Lenti Orf C 
or Lenti empty vector virus (MOI = 5, incubated for 72 hours).  Cells were harvested and 
cell fractions were isolated as previously described using the MitoProfile® benchtop 
mitochondrial isolation kit for cultured cells (Mitosciences®).  Mitochondrial fractions 
were lysed using Chaps® Cell Extract Buffer as previously described, and nuclear 
fractions were washed with Reagent B (MitoProfile® benchtop mitochondrial isolation 
kit for cultured cells; Mitosciences®) and lysed with Dignam C buffer as previously 
described.  Protein concentrations were determined via the Micro BCA™ protein assay 
kit (Thermoscientific®) as previously described.  Samples were loaded onto a Nu-




antioxidant, and run at 200 V constant for 50 minutes.  Staurosporine (5 µM) treated 
NIH-3T3 cells (cytosolic fraction) were used as a positive apoptosis control.  Proteins 
were transferred to an Immobilon™ transfer membrane (Millipore™) and run at 150 
mAmps constant for two hours.  Membrane was washed in TBS buffer (five minutes) and 
incubated with blotto at room temperature for 30 minutes.  Membrane was washed again 
with TBS buffer (three times, five minutes each) and primary AIF antibody (Cell 
Signaling technology®) was diluted in primary antibody dilution buffer (1:1000) and 
allowed to incubate with membrane overnight with rocking at 4°C.   
Twenty-four hours later the membrane was washed with TBS (three times, five 
minutes each) and secondary antibody (Anti-Rb IgG HRP-linked, 1:2000) was applied 
and incubated at room temperature for 90 minutes.  Membrane was then processed as 
previously described and developed with TMB western blot kit (KPL™). 
The preceding experiment was repeated twice using the same procedure but by 
transfecting either NIH-3T3 or HeLa cells with pKH3/pKH3-Orf C.  For each 
transfection reaction we used 3 x 10
6
 cells per 100 mm tissue culture plate (4 plates total, 
performed in duplicate to maximize cell products), incubated 24 hours until cells were 
approximately 60-80% confluent, and then performed the transfections.  We combined 40 
µL FuGene® HD to 500 µL Opti-MEM in polystyrene tubes and incubated this mixture 
for five minutes at room temperature.  Ten µg DNA (pKH3 or pKH3-Orf C) was added 
to the Fu-Gene®/Opti-MEM mixture and incubated it for 15 minutes at room 
temperature, and then layered onto the NIH-3T3 or HeLa cells.  Cells were incubated for 






Proteinase K digestion.  To more accurately determine the submitochondrial location of 
Orf C, a proteinase K digestion was performed on intact mitochondria isolated from 
HeLa cells transfected with pKH3/pKH3-Orf C as described above.  The mitochondria 
were isolated as previously described using the MitoProfile® benchtop mitochondrial 
isolation kit for cultured cells (Mitosciences®), with the exception that the mitochondrial 
pellet was left intact.  Mitochondria were then treated with proteinase K (0.2 µg) for 15 
or 30 minutes, with a non-treated control sample and a mitochondrial sample lysed with 
RIPA buffer included for comparison.  Samples were placed at 4°C with rotation for one 
hour, and then centrifuged for 15 minutes at 14,000 rpm.  Protein concentrations were 
determined via the Micro BCA™ protein assay kit (Thermoscientific®) as previously 
described.   
Protein samples (20 µg) were heated to 70°C for ten minutes and centrifuged at 
14,000 rpm for 1 minute.  Samples were then loaded onto a Nu-PAGE® Bis-Tris 12% 
acrylamide gel with MES buffer and 0.5 mL Nu-PAGE® antioxidant, and run at 200 V 
constant for 60 minutes.  Proteins were transferred to an Immobilon™ transfer membrane 
(Millipore™) and run at 150 mAmps constant for four hours.  The membrane was rinsed 
with TBS wash for five minutes and incubated in blotto at room temperature for one 
hour.  Membrane was again washed with TBS (three times for five minutes each) and the 
primary antibody (XHA (12CA5) 1:1000) was applied.  Membrane was incubated 
overnight at 4°C with rocking.  Twenty-four hours later the membrane was washed with 
TBS (three times, five minutes each) and secondary antibody (G x M IgG, HRP-linked, 




processed as previously described and developed with TMB western blot kit (KPL™).  
The same membrane was re-probed using a Bcl-2 monoclonal antibody (1:1000) as a 
control, with an appropriate secondary antibody (anti-Rb IgG HRP, 1:2000) applied using 
the previously outlined procedure.  
 
Results 
AIM 1. To construct a recombinant lentivirus expressing WDSV Orf C and assess its 
affect on cell growth. 
Production of recombinant WDSV Orf C lentivirus.  
 Previous experiments assessing the in vitro affects of Orf C utilized standard 
transient transfections with pKH3-Orf C.  To further characterize WDSV Orf C a more 
efficient delivery system was desired to maximize the effects of Orf C.  We chose to use 
a recombinant Lentivirus system because we anticipated this expression system would be 
more efficient at introducing Orf C into various target cells.  Another advantage of this 
system is that the Orf C-expressing recombinant lentivirus is self inactivating, which is a 
necessary feature for future in vivo virus experiments.  Individual plasmids physically 
separate the env, pol, and gag-pro sequences required for viral replication.  By using a 
replication incompetent virus for the in vivo studies we could ensure that the viral effects 
were limited to the target cells (specifically tumor cells), and eliminated the confounding 




A recombinant WDSV Orf C lentivirus vector was constructed by cloning the orf 
c open reading frame into the pLVX-Puro vector.   The Orf C lentivirus and the empty 
vector lentivirus were pseudotyped with either vesicular stomatitis virus glycoprotein G 
(VSV-G) or a mouse/rat ecotropic retrovirus glycoprotein.  By using the ecotropic virus 
we added an additional biosafety precaution as this virus will only infect mouse or rat 
cells.  In contrast, the VSV-G virus infects multiple cells types, including human cells.  
Our initial virus production using the Lenti-X™ HT Packaging System produced 
virus of low concentration, with the highest initial titers of VSV-G Lenti Orf C virus 
reaching 1 x 10
5
 cfu/mL.  We ultracentrifuged the virus to obtain a more concentrated 
virus sample and were able to increase the concentration of the VSV-G Lenti Orf C virus 
to 2.1 x 10
6
 cfu/mL.  The highest titers of ecotropic Lenti Orf C were 1 x 10
6
 cfu/mL; 
however, most were significantly lower. 
 Similar challenges were encountered when producing both VSV-G Lenti empty 
vector and ecotropic Lenti empty vector viruses, with the highest obtained titers reaching 
1 x 10
7
 cfu/mL and 1 x 10
5
 cfu/mL, respectively.  We investigated potential factors 
contributing to our low virus levels, including effects of freezing and time from 
transfection to virus harvest.  There was no appreciable concentration difference in virus 
that had been frozen at -80°C versus virus placed on ice and immediately titrated (6 x 10
4
 
cfu/mL, 7 x 10
4
 cfu/mL, respectively).  Since we harvested our virus 48 hours post-
transfection we examined additional time points to determine if increased virus 
concentrations occurred outside of the recommended 48 hours.  The results examining 




concentration as time progressed (1 x 10
4
 cfu/mL, 5 x 10
4




 The highest virus concentrations were obtained using ultracentrifugation 
following virus production.  We employed this technique on numerous occasions to 
enhance virus concentrations to levels high enough to effectively perform our in vitro 
experiments. 
Orf C-expressing lentivirus reduces cell viability 
Previous studies confirmed WDSV Orf C expression in regressing tumors by 
terminal deoxynucleotidyl transferase bioton-dUTP nick end labeling (TUNEL) 
demonstrated tumor cells undergoing apoptosis (Rovnak et al., 2007; Nudson et al., 2003; 
Rovnak and Quackenbush, 2010).  When Orf C was overexpressed in cultured cells 
mitochondrial function was altered and apoptosis was induced (Nudson et al., 2003).  
These studies suggested that Orf C may function as an oncolytic protein.     
To evaluate the potential of Lenti Orf C virus as an oncolytic therapeutic, we used 
a cell proliferation assay to screen various cell lines to evaluate Orf C’s effect on cell 
viability.  Following infection of 4T1 (mouse mammary tumor), MCA-205 (mouse 
sarcoma tumor) and NIH-3T3 (mouse fibroblast) cells with Lenti Orf C virus or Lenti 
empty vector control virus, cell viability was measured with Cell Titer 96
®
 AQueous One 
solution.  Our goal was to find a mouse tumor cell line that consistently exhibited 
apoptosis in association with Lenti Orf C virus infection for use in future in vitro and in 




To determine the ideal concentration of 4T1 cells to plate in a 96-well plate for 
the cell viability assays, we performed a pilot experiment.  We plated varying numbers of 
cells with the goal of assessing cell viability over a five day period.  The cell 
concentrations used ranged from 7 x 10
3
 cells/well to 2.8 x 10
5
 cells/well.  The 4T1 cells 
demonstrated very rapid growth with the highest cell concentration (2.8 x 10
5
 cells/well) 
showing 100% confluency within 24 hours, and the lowest cell concentration (7 x 10
3
 
cells/well) was 100% confluent at four days after plating the cells.   
We next established a growth curve for 4T1 cells using 2.5 x 10
3
 cells/well in a 96 
well plate, measuring cell viability (without virus effects) over a four day period (Figure 
1).  The purpose of this experiment was to determine the optimal time frame for cell 
growth following various experimental manipulations.  4T1 cell growth rate was maximal 
between days two to four; therefore we concluded that cell viability should be assessed 
between 48-72 hours post cell plating – within the time period of maximal cell growth, 
but prior to cell confluency and overgrowth.  We also determined the optimal cell 
concentration for in vitro experiments in a 96 well plate was 2.5 x 10
3
 cells/well, as this 







Figure 1. Growth curve of 4T1 cells.  2.5 x 10
3
 cells per well were plated and cell 
viability measured by MTS assay. The mean OD490 readings from six replicate wells was 
determined for each time point. 
 
Once we established an optimal cell concentration for use in the 96 well plates, 
we proceeded with the cell viability analysis in order to screen various cell lines for use 
in our in vitro experiments.  We first used the 4T1 mouse mammary tumor cell line and 
infected cells with either Lenti Orf C virus (VSV-G) or Lenti empty vector virus (VSV-
G) (n=5) with a multiplicity of infection (MOI) of 1.5.  Cell viability was analyzed at 24, 
72, and 96 hours post-infection with the CellTiter96® Aqueous One Solution Cell 
Proliferation Assay (MTS assay).  No difference in cell viability was observed between 





Figure 2. No significant reduction of 4T1 cells following infection with Lenti Orf C virus 
(MOI=1.5).  3.5 x 10
3
 cells per well were plated and cell viability measured by MTS 
assay.  The mean (OD490) readings from five replicate wells were determined for each 
timepoint. 
 
Since no observable decrease in cell viability was observed with Lenti Orf C 
infection, we surmised we needed to increase our virus concentration.  Given that our 
virus is replication incompetent, we rely solely on individual cells being infected, and 
would not see virus spread throughout the culture.  This virus safety feature may 
necessitate the use of slightly higher virus concentrations than initially anticipated.   
We therefore repeated this experiment with increased MOI of 5, 10, and 100.  A 
significant decrease in cell viability was observed at MOI=100 (P<0.00006), with the 
percent of viable cells decreased to 45% in comparison to the uninfected control cells 
(Figure 3).  However, when we repeated this experiment using appropriate Lenti empty 
vector controls (MOI=100), the same decrease in cell viability was observed in our Lenti 




that at the high virus concentration of MOI=100, cell viability decreases independently of 
Orf C effects. 
 
Figure 3. 4T1 cells infected with Lenti Orf C virus show a significant reduction at 
MOI=100.   2.5 x 10
3
 cells per well were plated and cell viability measured by MTS 
assay three days post infection.  The mean ± standard deviation of OD490 readings from 
replicates of six wells (Lenti Orf C, MOI=100, n=3) was determined and normalized to % 
viability. 
 
To control for interassay differences with the two viruses, we repeated the cell 
viability experiment using 4T1 cells infected with Lenti Orf C and Lenti empty vector 
viruses at a MOI of 1, 5, or 10.  A decrease in cell viability was observed in cells infected 
with Lenti Orf C virus at a MOI of 5 in comparison to the Lenti empty vector virus 
(P<0.003) (Figure 4), with the percent of viable cells decreased to 72% of the Lenti 
empty vector infected control cells.  However, this decrease in cell viability was not 
present at a MOI of 10 (data not shown).  The Lenti empty vector virus did not have an 





Figure 4. 4T1 cells infected with Lenti Orf C virus show a significant reduction at 
MOI=5.  2.5 x 10
3
 cells per well were plated and cell viability measured by MTS assay 
three days post infection.  The mean ± standard deviation of OD490 readings from 
replicates of three wells was determined and normalized to % viability. 
 
The results from Figure 4 were promising as we did observe a significant decrease 
in viability of Orf C-expressing 4T1 cells at a MOI=5.  However, the failure to 
significantly reduce cell viability in Orf C-expressing 4T1 cells at a MOI=10 led us to 
conclude that we should concurrently experiment with a non-tumor cell line as a control.  
We used NIH-3T3 cells, a mouse fibroblast cell line, as a non-tumor cell to control for 
any anti-apoptotic aberrations that may be present in the 4T1 cell line. 
We infected both 4T1 and NIH-3T3 cells using a MOI of 1, 5, or 10 and results 
were analyzed 48 hours post-infection with the CellTiter Blue® MTS assay.  This 
alternative assay was used for this experiment based on its ability to be used in 
conjunction with the Apo-One® Homogenous Caspase 3/7 assay (Promega™) (no results 





cell viability with increasing virus concentration in both 4T1 and NIH-3T3 cells.  
However, a significant decrease was only observed in the NIH-3T3 cell line at MOI’s of 
5 and 10 (p < 0.035) (Figure 5), with the percent of viable cells decreased to 59% and 
65% in comparison to the Lenti empty vector control cells, respectively.   
 
Figure 5. NIH-3T3 cells infected with Lenti Orf C virus show a significant reduction at a 
MOI of 5 and 10.  2.5 x 10
3
 cells per well were plated and cell viability measured by 
MTS assay (CellTiter Blue®) two days post infection.  The mean ± standard deviation of 
OD530(20)Ex/590(20)Em readings from replicates of six wells was determined and normalized 
to % viability. 
 
We repeated the experiment from Figure 5 and included the additional time points 
of 24 and 72 hours post-infection.  The 24 and 72 hour time points showed no significant 
difference in cell viability between the Lenti Orf C and Lenti empty vector virus infected 
4T1 or NIH-3T3 cells (data not shown).  However, at 48 hours post-infection, the NIH-
3T3 cells showed a significant decrease in viability at MOIs of 1 (P<0.004) and 5 








comparison to the Lenti empty vector control cells.  A decreased viability was also 
present at a MOI of 10, however the decrease was not significant, possibly related to our 
small sample size.  4T1 cells exhibited no decrease in cell viability with Lenti Orf C 
infection (Figure 6).   
 
Figure 6.  NIH-3T3 cells infected with Lenti Orf C virus show a significant reduction at a 
MOI of 1 and 5.  2.5 x 10
3
 cells per well were plated and cell viability measured by MTS 
assay two days post infection.  The mean ± standard deviation of OD490 readings from 
replicates of six wells was determined and normalized to % viability. 
 
Our results from Figures 4-6 demonstrate the difficulties we had in using the 4T1 
cell line for our viability assays.  In comparison to the NIH-3T3 cells, 4T1 Orf C-
expressing cells did not consistently decrease cell viability.  We concluded that based on 
these results, the 4T1 cell line was not amenable to the in vitro studies we needed to 
conduct to assess the apoptotic ability of Lenti Orf C virus.  The rapid growth rate of 4T1 
cells is likely the major characteristic that made them resistant to exhibiting consistent 




We replaced the 4T1 cells with an alternative mouse tumor cell, MCA-205.  
MCA-205 is a mouse sarcoma cell line that has been well-characterized in vitro and in 
vivo.  We repeated cell viability experiments using NIH-3T3 and MCA-205 cells infected 
at a MOI of 10 or 20, and examined time points at 24, 48, and 72 hours post-infection 
(Figures 7-9).  A significant decrease in cell viability was observed 24 hours post-
infection at a MOI of 10 in both MCA-205 (P<0.0005) and NIH-3T3 cells (P<0.03).  At 
a MOI of 10, viability of MCA-205 cells expressing Orf C decreased to 80% in 
comparison to the Lenti empty vector controls.  The NIH-3T3 Orf C-expressing cell 
viability decreased to 95% in comparison to the Lenti empty vector controls.  There was 
also a mean decrease in cell viability at a MOI of 20 in both cell lines that was not 
statistically significant (Figure 7).   
 
Figure 7.  MCA-205 and NIH-3T3 cells infected with Lenti Orf C virus demonstrate 
significant reduction at a MOI of 10.  2.5 x 10
3
 cells per well were plated and cell 
viability measured by MTS assay one day post infection.  The mean ± standard deviation 






At 48 hours post-infection a significant decrease in cell viability was observed at 
a MOI of 10 in both MCA-205 (P<0.00006) and NIH-3T3 cells (P<0.00003) and a MOI 
of 20 in MCA-205 (P< 0.0002) and NIH-3T3 (P<0.04) cells.  The NIH-3T3 cells showed 
the most significant cell viability decrease at a MOI of 20 two days post-infection, with a 
cell viability of 45% in comparison to the cells infected with Lenti empty vector virus.  
The MCA-205 cells also showed a significant cell viability decrease at a MOI of 20, with 
a cell viability of 55% in comparison to Lenti empty vector virus (Figure 8). 
   
Figure 8.  MCA-205 and NIH-3T3 cells infected with Lenti Orf C virus demonstrate 
significant reduction at a MOI of 10 and 20.  2.5 x 10
3
 cells per well were plated and cell 
viability measured by MTS assay two days post infection.  The mean ± standard 
deviation of OD490 readings from replicates of three-six wells (MOI=10, n=6; MOI=20, 
n=3) was determined and normalized to % viability.  
  
A significant decrease in cell viability was observed 72 hours post-infection at a 
MOI of 10 in NIH-3T3 cells (P<0.006) and a MOI of 20 in MCA-205 (P< 0.03) and 
NIH-3T3 (P<0.007) cells.  The NIH-3T3 cells again showed the most significant 




41% in comparison to the cells infected with Lenti empty vector virus.  The MCA-205 
cells demonstrated a cell viability of 88% at a MOI of 20 in comparison to Lenti empty 
vector virus infected cells (Figure 9).  The results from Figures 7-9 led us to conclude 
that the most significant decreases in cell viability occurred 48 hours post infection, and 
that these decreases, while present in both the MCA-205 and NIH-3T3 cell lines, were 
most pronounced in the NIH-3T3 cells.  We also concluded that given these results, the 
MCA-205 cells would serve as an appropriate in vitro model of Orf C-induced apoptosis. 
 
Figure 9.  NIH-3T3 (MOI 10 and 20) and MCA-205 (MOI=20) cells infected with Lenti 
Orf C virus demonstrate significant reduction of viable cells.  2.5 x 10
3
 cells per well 
were plated and cell viability measured by MTS assay three days post infection.  The 
mean ± standard deviation of OD490 readings from replicates of six wells was determined 







AIM 2. To determine the subcellular localization of the lentivirus expressed Orf C. 
Orf C is expressed in mitochondrial, nuclear, and cytosolic cell fractions  
Given previous research by Nudson et al. (2003) we believed Orf C would be 
expressed in the cell mitochondria.  We transfected HeLa cells with pKH3-Orf C and 
examined the mitochondrial and cytosolic cell fractions for Orf C expression.  We found 
that Orf C was expressed in both the mitochondrial and cytosolic cell fractions, indicating 
that Orf C is not exclusively located in the mitochondria (Figure 10).   
 
Figure 10. WDSV Orf C is present in mitochondrial and cytosolic cell fractions of HeLa 
cells transfected with pKH3-Orf C.  Enriched mitochondrial and cytosolic cell lysates 
were immunoprecipitated and HA-tagged Orf C was detected with anti-HA antibody 
(12CA5).  Lysates from HeLa cells transfected with Orf C (pKH3-Orf C) or control 
vector (pKH3) serve as controls.   
 
Previous unpublished results from the Quackenbush laboratory (Hronek, Rovnak 
and Quackenbush, unpublished) indicated that WDSV Orf C was present in nuclear 
extracts from tumors.  To examine potential Orf C expression in the cell nuclei and to 
confirm previous observations, we transfected HeLa cells and isolated the mitochondrial, 
nuclear, and cytosolic cell fractions.  We observed robust Orf C expression in all cell 





Figure 11. WDSV Orf C is present in mitochondrial, cytosolic, and nuclear cell fractions 
of HeLa cells transfected with pKH3-Orf C.  Enriched mitochondrial (mito), cytosolic 
(cyto), and nuclear (nucl) cell lysates were analyzed via Western blot and HA-tagged Orf 
C was detected with monoclonal anti-HA antibody (12CA5).   
 
To further examine this intranuclear location of Orf C, we used 4T1 and HeLa 
cells infected with Lenti Orf C virus (estimated MOI=0.006) and analyzed mitochondrial, 
nuclear, and cytosolic cell fractions.  Orf C was expressed in all cell fractions, however 
the nuclear cell fraction showed the most robust Orf C expression (Figure 12).  
 
Figure 12. WDSV Orf C is expressed in mitochondria, nuclear, and cytosolic fractions. 
4T1 and HeLa cells were infected with Lenti Orf C virus (est. MOI=0.006) and separated 
into mitochondrial (mito), nuclear, (nucl), and cytosolic (cyto) fractions 48 hrs post 
infection and analyzed by western blot. HA-tagged Orf C was detected with anti-HA 
(12CA5) monoclonal antibody.  Lysates from 4T1 cells transfected with Orf C (pKH3-





Based on the results of Figures 11-12 we concluded that Orf C was expressed in 
mitochondrial, nuclear, and cytosolic cell fractions following transient transfection and 
Lenti Orf C virus infection.  Although the results from the Lenti Orf C cell infections 
(Figure 12) showed the same localization pattern as the pKH3-Orf C transfections 
(Figure 11), the intensity of Orf C expression differed between the two experiments.  The 
Lenti Orf C infection experiment showed that while Orf C continued to be expressed in 
all cell fractions, the nuclear cell fraction exhibited the most robust Orf C expression.  
The pKH3-Orf C transfection experiments showed relatively equal amounts of Orf C 
expression in the various cell fractions.  This difference in Orf C expression intensity 
may suggest differences in subcellular localization that are dependent on the method of 
Orf C cellular introduction.   
 
AIM 3. To determine the mechanism of Orf C-induced apoptosis 
Orf C-induced apoptosis functions via a caspase-independent pathway 
To elucidate the underlying mechanism(s) of Orf C-induced apoptosis, we 
examined activated caspases 3, 6, 9, 12, and cleaved PARP following infection with Orf 
C.  Activation of a specific caspase was identified by western blot analysis of its cleaved 
form.  We used multiple cell lines for caspase analysis, including 4T1, MCA-205, and 
NIH-3T3 cells.  Cells were infected with either Lenti Orf C or Lenti empty vector virus 




We initially used IP buffer to lyse our cell samples and found one unique finding 
in that cleaved PARP was activated in all 4T1 cell samples (uninfected, Lenti empty 
vector infected, and Lenti Orf C infected) (data not shown).  Activation of PARP in the 
4T1 tumor cell line is not entirely unexpected.  PARP is often activated in cancer cells as 
it facilitates DNA repair and promotes uncontrolled cell growth (Helleday et al., 2005). 
Caspase-3 is an effector caspase, which is directly activated/cleaved by caspases 
7, 8, 9, and 10 during caspase-dependent apoptosis (Salvesen and Riedl, 2008).  Our 
results showed no evidence of activation of caspase 3 (Figure 13) or any of the other 
caspases we examined (data not shown) following infection with Lenti Orf C.   
 
Figure 13. Cleaved caspase-3 is not detectable in Orf C expressing cells.  4T1 and NIH-
3T3 cells were infected with Lenti Orf C (MOI=10) or Lenti empty vector control virus 
(Empty). Uninfected cells were used as a negative control and staurosporine (stauro.) 
treated cells (5 µM) served as a positive apoptosis control.  Cleaved caspase-3 Rabbit 
mAb (Asp175) (1:1000) was used to detect the cleaved caspase.  
 
We repeated this experiment substituting Chaps® cell extract buffer for the IP 
buffer, as a reference was found suggesting this buffer is more appropriate for caspase 




evidence of activation following infection with Lenti Orf C (data not shown).  These 
results suggest that Orf C induces apoptosis via a caspase independent mechanism.   
Orf C interacts with ANT and Bax 
In our quest to identify a specific Orf C target in mitochondria and to further 
define the mechanism(s) of Orf C-induced apoptosis, we performed immunoprecipitation 
assays to assess Orf C interaction with apoptosis-specific proteins.  Based on a previous 
study that showed alteration of the mitochondrial membrane potential and work by others 
demonstrating interaction of other viral proteins with components of the mitochondria 
permeability transition pore complex (PTPC), we first examined two components of the 
PTPC, VDAC and ANT (Nudson et al., 2003; Boya et al., 2001).  Mitochondrial lysates 
harvested from HeLa cells transfected with pKH3 or pKH3-Orf C were 
immunoprecipated using anti-VDAC and anti-ANT antibodies.  We were able to detect 
Orf C interaction with the ANT antibody, but not VDAC antibody via co-IP (Figure 14 







Figure 14. WDSV Orf C is present in a complex with adenine nucleotide translocase 
(ANT).  Enriched mitochondrial lysates were immunoprecipitated with a mouse anti-
ANT monoclonal antibody.  HA-tagged Orf C was detected with anti-HA antibody 
(12CA5).  Lysate represents 15% of the total amount used for immunoprecipitation.        
 
We next examined possible interaction of Orf C with Bcl-2 and Bax as both are 
pro-apoptotic proteins.  Bcl-2 is located in the outer mitochondrial (OM) membrane and 
Bax is a Bcl-2 family protein that mediates permeabilization of the OM membrane, 
inducing apoptosis via disruption of the OM membrane (Kroemer et al., 2007).  In a 
similar fashion to the co-IP of Orf C with ANT antibody, a small amount of the expressed 
Orf C was co-IP with Bax (Figure 15), but not with Bcl-2.   These data suggest that Orf 
C may be interacting with ANT and Bax, however the lack of a robust band indicates that 





Figure 15. WDSV Orf C is present in a complex with Bax (Bcl-2 family) in the 
mitochondrial and cytosolic fractions.  Enriched mitochondrial lysates were 
immunoprecipitated with a mouse anti-Bax monoclonal antibody.  HA-tagged Orf C was 
detected with anti-HA antibody (12CA5).   
 
Orf C localizes to the inner/inter-mitochondrial membrane space 
To more definitively determine the submitochondrial localization of Orf C we 
purified mitochondria from Orf C expressing cells and from control cells.  Mitochondrial 
samples were treated with proteinase K or control buffer.  Treatment of mitochondria 
with proteinase K should digest proteins located in the OM membrane.  Bcl-2, a known 
OM membrane protein, was used as a control and was not detected in the proteinase K 
treated samples.  We found that Orf C expression remains intact with proteinase K 
treatment (Figure 16), indicating that Orf C is not located in the OM membrane but 
rather resides in either the inner mitochondrial membrane or the inter-mitochondrial 
membrane space.  However, repeat experiments have shown some ambiguous results and 
further experiments are underway to clarify the association of Orf C with the outer 






Figure 16.  WDSV Orf C is not associated with the outer mitochondrial membrane.  
Mitochondria isolated from HeLa cells transfected with pKH3-Orf C or pKH3 control 
and treated with proteinase K for 15 or 30 minutes.  Bcl-2 used as a control.  Samples 
analyzed by western blot with anti-HA (12CA5) monoclonal antibody used to detect HA-
tagged Orf C. 
 
Interaction of Orf C with AIF 
Our results indicate that Orf C appears to induce apoptosis via a caspase 
independent mechanism.  Given the results of the proteinase K experiment, we were 
interested in the interaction of Orf C with AIF (apoptosis-inducing factor) since AIF is 
located in the inter-membrane space of the mitochondria.  We were additionally 
interested in this protein given the robust expression of Orf C in the nucleus, and the 
tendency of AIF to translocate to the nucleus upon activation.  We examined NIH-3T3 
and MCA-205 cell fractions following Lenti Orf C and Lenti empty vector virus infection 
and found AIF expression in all cell fractions (mitochondrial, cytoplasmic, and nuclear) 
via western blot, with slightly more robust expression in the nuclear cell fraction of Lenti 





Figure 17. AIF is expressed in the mitochondria (M), cytosolic (C), and nuclear (N) cell 
fractions of NIH-3T3 and MCA-205 cells infected with Lenti Orf C or Lenti empty 
vector virus (MOI=5). NIH-3T3 treated with staurosporine (S) (5 µM) used as a positive 
apoptosis control. Samples analyzed by western blot with anti-Rb IgG HRP-linked 
(1:2000) monoclonal antibody used to detect Anti-AIF Ab.  
 
AIF expression was also demonstrated in all cell fractions following transfection 
of NIH-3T3 cells (Figure 18) and HeLa cells (Figure 19) with pKH3 or pKH3-Orf C.  
Expression of Orf C was confirmed in pKH3-Orf C transfected HeLa cells (Figure 19).  
Although AIF is expressed in all cell fractions, the most robust expressions were 







Figure 18. AIF is expressed in mitochondria (M), cytosolic (C), and nuclear (N) cell 
fractions of NIH-3T3 cells transfected with Orf C (PKH3-Orf C) or control vector 
(pKH3).  NIH-3T3 treated with staurosporine (S) (5 µM) used as a positive apoptosis 
control. Samples analyzed by western blot with anti-Rb IgG HRP-linked (1:2000) 
monoclonal antibody used to detect Anti-AIF Ab.  
 
 
Figure 19.  AIF is expressed in mitochondria (M), cytosolic (C), and nuclear (N) cell 
fractions of HeLa cells transfected with Orf C (PKH3-Orf C) or control vector (pKH3).  
NIH-3T3 treated with staurosporine (S) (5 µM) used as a positive apoptosis control. Orf 
C expression confirmed (anti-HA (12CA5) monoclonal antibody).  Samples analyzed by 






These data suggest that AIF is being cleaved from its inter-mitochondrial 
membrane location and translocating to the nucleus.  However, AIF activation does not 
appear to be limited to Orf C-expressing cells.  Further studies are therefore needed to 
examine the exact nature of the relationship between Orf C and AIF. 
 
Discussion  
Recombinant Orf C lentivirus expression system 
 In fulfillment of specific AIM 1, we successfully created an Orf C-expressing 
lentivirus (Lenti Orf C) that was confirmed via DNA sequencing.  This recombinant virus 
was created for two purposes.  The first was to have a means of introducing Orf C into 
target cells with a high degree of efficiency.  The second purpose was focused on its 
future in vivo use – this recombinant Orf C-expressing virus is replication incompetent as 
it lacks gag, pol, and env, which would be required for viral replication.   
This characteristic of replication incompetency conveys several biosafety 
features.  By using a replication incompetent virus for the in vivo studies we can ensure 
that the viral effects are limited to the target tumor cells and eliminate the risks associated 
with systemic viral infections.  We further enhanced the safety of using this virus in 
research studies by producing an Ecotropic Lenti Orf C virus that is specific to mouse/rat 
cells.  By using a virus with an ecotropic envelope we are ensuring that the virus will 




We encountered difficulties in producing high virus titers with both the VSV-G 
and Ecotropic Lenti Orf C viruses.  While we were able to obtain virus, the virus 
produced yielded consistently low virus titers.  After several attempts at producing virus 
that resulted in low viral titers, we decided that we could enhance our virus titers by 
ultracentrifugation.  This step increased our virus titers by approximately ten-fold, and 
became a necessary procedure following virus production.  However, even with 





 cfu/mL (Ecotropic).  At these virus concentrations we were able to 
proceed with our in vitro experiments, but needed to continually grow virus throughout 
the series of thesis experiments as we needed relatively large virus volumes to conduct 
our experiments. 
We investigated other potential causes of low virus levels.  We examined virus 
titers from virus that had been frozen at -80°C and compared these titers to the same virus 
that was not frozen before use.  No appreciable difference was observed indicating that 
freeze/thaw did not have a large effect on virus titers, at least after one freeze/thaw cycle.  
We also investigated harvesting viral supernatants outside of the 48 hour recommended 
time point post-transfection.  We harvested the supernatants at an earlier time point (24 
hours) and a later time point (72 hours) post-transfection.  We did observe a slightly 
higher virus titration in association with the 72 hour time point in comparison to both the 
24 and 48 hour time points (10
4
 cfu/mL at 24 hours, 5 x 10
4
 cfu/mL at 48 hours, and 10
5
 
cfu/mL at 72 hours).  While this increase was not high enough to significantly benefit our 
in vitro experiments we did modify our virus harvest technique to delay collection until 




For future experimental in vivo use of the Lenti Orf C virus it would be beneficial 
to produce large amounts of virus and ultracentrifuge this virus.  Resuspending the virus 
in relatively small amounts of buffer solution (1/1000
th
 of original volume) will assist 
with producing virus titers with high concentrations to effectively complete the in vivo 
injections.  Although challenging, the benefit of having a replication incompetent virus is 
necessary for future in vivo studies assessing the oncolytic potential of Lenti Orf C virus.  
 
Orf C-expressing cells demonstrate decreased cell viability 
 To screen various cell lines for their potential use as an in vitro cell model of Orf 
C-induced apoptosis, we used a MTS cell proliferation assay to assess cell viability 
following Lenti Orf C and Lenti empty vector virus infections.  We initially focused on 
the 4T1 mouse mammary tumor cell line for several reasons.  Since this cell line is a 
mouse mammary tumor cell line, its use would transition well from in vitro to in vivo 
experimentation.  Mouse mammary tumor cells are easily injected into the mammary fat 
pads of mice and following tumor growth, easily accessible for experimental 
manipulation.  In addition, these cells have been extensively used at Colorado State 
University in various oncology studies and thus are well characterized.  We know the 
tumor growth rate timeline from point of injection until potential ulceration and could 
plan an in vivo experiment around this known timeline.     
 Unfortunately the 4T1 cell line did not exhibit consistent decreases in cell 
viability following Lenti Orf C infection (Figures 2, 5, and 6).  To determine if the 




line, we refined our in vitro assay and analyzed an alternative non-tumor cell line in 
conjunction with the 4T1 cells.  We used a mouse fibroblast cell line, NIH-3T3 cells, to 
control for any aberrations or apoptosis-resistant properties with the 4T1 tumor cell line 
and found that the NIH-3T3 cells exhibited significant decreases in cell viability that 
correlated with increasing Lenti Orf C virus concentrations (Figures 5-6).  With the NIH-
3T3 cell line we finally demonstrated that Lenti Orf C could induce significant reductions 
in cell viability.   
There are likely several reasons the 4T1 cells failed to consistently exhibit Orf C-
induced apoptosis in our studies.  The most pronounced cause of apoptosis-resistance is 
most likely related to the very rapid growth rate of 4T1 cells.  While the 4T1 cells 
showed minor decreases in viability in association with Lenti Orf C infection, these 
decreases were most often not significant and not consistently repeatable.  We believe 
that while Orf C was inducing some degree of apoptosis in the 4T1 cell line, the rapid 
growth rate of these cells made any apoptosis-induced decreases difficult to detect with 
our MTS cell proliferation assays. 
The lack of perceivable cell death in the 4T1 cells with Lenti Orf C infection led 
us to experiment with an alternative tumor cell line, MCA-205 cells, a mouse sarcoma 
cell line.  We chose this cell line because similar to the 4T1 cells it had also been 
extensively used for oncology studies at CSU and was well characterized.  We ran a 
series of cell viability experiments examining MCA-205 and NIH-3T3 cells infected with 
various virus concentrations and analyzed different time points post-infection.  We 




viability following Lenti Orf C virus infection (Figures 7-9), and there was a direct 
relationship between decreasing cell viability and increasing virus concentration.   
These results indicate that the observed decreased viability with Lenti Orf C 
infection is solely attributable to Orf C, and serves as further evidence that Orf C induces 
apoptosis.  In addition, this series of experiments using MCA-205 cells demonstrate that 
this tumor cell line shows consistent apoptosis when infected with Lenti Orf C virus and 
suggests the MCA-205 cells will serve as a suitable in vitro model (and potential in vivo 
model) of Orf C-induced apoptosis.       
 
Orf C is expressed in mitochondrial, nuclear, and cytosolic cell fractions 
 In our quest to discover the mechanism(s) of Orf C-induced apoptosis, we needed 
to determine the intracellular target of Orf C.  We initially determined the intracellular 
location of Orf C following transfection of HeLa cells.  Previous studies had 
demonstrated Orf C expression in the cell mitochondria following cell transfections with 
pKH3-Orf C (Nudson et al., 2003).  In addition to examining the mitochondrial cell 
fractions, we examined cytosolic and nuclear fractions for Orf C expression following 
pKH3-Orf C transfection of HeLa cells (Figures 10-11).  Based on the previous results of 
Nudson et al. (2003), we expected to observe the most robust Orf C expression in the 
mitochondrial cell fraction.  While we did observe Orf C expression in the mitochondria, 
the cytosolic and nuclear fractions also exhibited robust Orf C expression (Figure 11).   
To determine if this subcellular localization pattern was demonstrable following 




cell fractions of 4T1and HeLa cells infected with Lenti Orf C virus.  While Orf C 
continued to be expressed in all cell fractions following infection, our Lenti Orf C results 
differed from our pKH3-Orf C transfections in the intensity of Orf C expression.  We 
found that following Lenti Orf C infection, Orf C expression was most robust in the 
nuclear extract (Figure 12).  This difference in Orf C expression intensity may suggest 
differences in subcellular localization that are dependent on the method of Orf C cellular 
introduction.  For example, in comparison to the pKH3-Orf C transient transfections, the 
use of a lentivirus introduction system may stimulate different pathways within the cell 
that localize Orf C to the nucleus.  Another potential explanation for this difference in Orf 
C expression intensity may be related to the timing of experiments.  Further studies 
examining subcellular Orf C localization along a defined timeline are warranted to 
determine if the sequence of events following Lenti Orf C infection affect the subcellular 
location of Orf C.  
We believe this finding of nuclear localization of Orf C is significant in decoding 
the mechanism(s) of Orf C-induced apoptosis.  Our findings of robust nuclear expression, 
coupled with the previous findings of mitochondrial expression, indicate that the 
mechanism of Orf C induced apoptosis may function at both the mitochondrial and the 
nuclear locations, and further studies are needed to determine which subcellular structure 
is targeted first by Orf C.  We additionally would like to determine which potential pro-






Orf C-induced apoptosis functions via a caspase-independent pathway 
In further efforts to elucidate the underlying mechanism(s) of Orf C-induced 
apoptosis, we focused on determining whether Orf-C induced apoptosis was occurring 
via a caspase-dependent or caspase-independent pathway.  Orf C has previously been 
shown to be associated with a decrease in mitochondria-associated cytochrome c 
(Nudson et al., 2003).  When cytochrome c is liberated from the mitochondrial membrane 
it will initiate a caspase-dependent apoptotic cascade by interacting with Apaf-1 
(Apoptotic protease activating factor-1) to form the apoptosome, which in turn activates 
procaspase-9 (Yuan et al., 2010).  Given this previous observation, we expected Orf C 
would initiate apoptosis via a caspase-dependent pathway, and that both caspases -9 and -
3 would be activated in Orf C-expressing cells.   
We examined a variety of caspases (3, 6, 9, 12, and cleaved PARP) and conducted 
experiments using multiple cell lines.  Although we initially used IP buffer to lyse our 
cell samples, we moved to an alternative buffer (Chaps® cell extract buffer), upon 
recommendation from the manufacturer.   Regardless of our experiment modifications 
and refinements, we were unable to show evidence of caspase activation following 
infection with Lenti Orf C (Figure 13).     
Given the lack of caspase activation it appears that Orf C induces apoptosis in a 
caspase-independent manner.  A variety of non-caspase cell proteases have been shown 
to cause apoptosis, such as AIF, endonuclease G (Endo-G), and OMI/HtrA2 (Omi stress-
regulated endoprotease/high temperature requirement protein A2) (Bröker et al, 2005; 




independent manner furthers our understanding of its basic mechanism of induced 
apoptosis and helps us focus on caspase-independent proteases and endonucleases as 
potential targets of Orf C-induced apoptosis.  
 
Orf C interacts with ANT and Bax 
Since a previous study had shown that Orf C targets the cell mitochondria and 
alters the mitochondrial membrane potential (Nudson et al., 2003), we hypothesized that 
the pro-apoptotic target of Orf C would reside in the transition pore complex.  This 
hypothesis was based on the knowledge that the mitochondrial membrane potential is 
controlled in part by the permeability transition pore complex (PTPC) (Kroemer et al., 
2007), and thus any membrane potential alterations could be the result of direct 
interaction with the PTPC.  Other viral proteins have been shown to exert apoptotic 
effects by interacting with these mitochondrial proteins.  For example, an HIV-1 
accessory protein, Vpr, has been shown to interact with ANT and induce cell death (Boya 
et al., 2004).  The X protein of Hepatitis B virus has also been shown to have pro-
apoptotic effects via its interaction with VDAC (Boya et al., 2004).  
Given that VDAC and ANT are integral components of the PTPC, we initially 
conducted experiments to determine if these were the mitochondrial targets of Orf C.  
While the results did not indicate a role for VDAC in Orf C-induced apoptosis, we did 
demonstrate that Orf C complexes with ANT (Figure 14).  We also examined known pro-
apoptotic proteins Bcl-2 and Bax and found that Orf C formed a complex with Bax 




mitochondrial (OM) membrane and induces apoptosis via disruption of the OM 
membrane (Kroemer et al., 2007).  Under normal cellular conditions Bax is located in the 
cytosol, but translocates to the OM membrane under specific apoptotic conditions, and 
can translocate in association with other Bcl-2 family members, Bak or Bid (Kroemer et 
al., 2007).   
While our data indicate that Orf C forms complexes with ANT and Bax, the 
results were not robust, suggesting that other complexes may be primary inducers of Orf 
C associated apoptosis.  Examples of such proteins could include Bak or Bid that can 
translocate to the OM membrane with Bax.  Further studies are needed to determine if 
there is a stronger association of Orf C with additional pro-apoptotic proteins.   
 
Orf C localizes to the inner/inter-mitochondrial membrane space 
Since we suspected Orf C may not be directly interacting with ANT and/or Bax, 
we conducted an experiment to narrow the search for other protein(s) of interest that 
directly target Orf C.  To more definitely determine the submitochondrial localization of 
Orf C we purified mitochondria from Orf C expressing cells and treated them with 
proteinase K.  Since proteinase K digests mitochondrial surface proteins, we could 
determine if Orf C was interacting with proteins at the outer mitochondrial membrane or 
the inner/inter-mitochondrial membrane space.  We found that Orf C expression remains 
intact with proteinase K treatment (Figure 16), indicating that Orf C interacts with 
proteins in the inner membrane or inter-mitochondrial membrane space.  This finding is 




represents significant progress towards determining the mechanism(s) of Orf C-induced 
apoptosis.   
 
Interaction of Orf C with AIF 
Given the previous results we can now focus on proteins located in the inner 
mitochondrial membrane and/or the inter-mitochondrial membrane space as potential Orf 
C targets.  One specific protein of particular interest is AIF (apoptosis-inducing factor).  
AIF is located in the inter-mitochondrial membrane space and induces apoptosis via a 
caspase-independent pathway.  Additionally, once it is activated/cleaved from the inter-
mitochondrial membrane space it translocates to the cell nucleus where it induces 
apoptosis by affecting chromatin condensation and DNA fragmentation (Bröker et al., 
2005).  Since we have observed significant Orf C expression in the cell nuclear fraction 
we were particularly interested if AIF was activated upon exposure to Orf C.   
We examined the mitochondrial, cytosolic, and nuclear cell fractions for AIF 
expression following exposure to Orf C (Figures 17-19).  We were able to detect AIF 
expression in all cell fractions, with the strongest expression in the mitochondrial and 
nuclear cell fractions in both experiments.  However, to show AIF activation is associated 
with Orf C, we were looking for AIF expression exclusively in the nuclear extract of the 
Orf C-expressing cells since AIF translocates to the cell nucleus following activation.  
Our results did not indicate exclusive AIF activation in the Orf C-expressing cells.  
However, it did appear that the Orf C-expressing cells showed slightly higher levels of 




was particularly prominent following the pKH3-Orf C transfections (Figures 18-19).  
This observation could indicate a possible interaction of Orf C with AIF, however, 
further studies examining the scope of their interaction is needed to confirm the results.   
Future studies examining the role of AIF would include an immunoprecipitation 
experiment to determine if AIF complexes with Orf C.  In addition, other caspase-
independent pro-apoptotic proteins should be examined for their role as potential Orf C 
targets.  One such protein is endonuclease G, which upon activation is cleaved from the 
mitochondria, and then (similar to AIF) translocates to the nucleus where it cleaves 
chromatin DNA and causes cellular apoptosis (Li et al., 2001; Bröker et al., 2005).     
 
Orf C potential as an oncolytic therapy 
Once the mechanism of Orf C-induced apoptosis has been clarified, it will be 
important to develop an in vivo model to assess the potential use of Orf C as an oncolytic 
therapy.  Our experiments thus far provide much of the groundwork necessary to assess 
the in vitro oncolytic potential of the Lenti Orf C virus.  We have created an ecotropic 
recombinant lentivirus that expresses Orf C and will be a reasonable method of 
introducing Orf C into target tumor cells.  We have also considered the biosafety aspect 
of future in vivo studies by creating a virus with an ecotropic envelop that will only infect 
the target rodent cells (not human cells) and additionally is replication incompetent – 
avoiding the complications associated with potential systemic infection.   
We have also identified an appropriate tumor cell line, the MCA-205 mouse 




have performed extensive experiments demonstrating that these tumor cells undergo 
apoptosis when infected in vitro with Lenti Orf C. 
While the exact mechanism(s) of Orf C-induced apoptosis has not been 
elucidated, we have made significant progress towards this goal.  Once this mechanism 
has been well defined, Lenti Orf C should be moved into an in vivo experimental mouse 
model.  For the in vivo model we propose using luciferase-expressing MCA-205 cells 
injected into the mammary fat pad of C57BL/6 mice.  Once the tumor cells grow into an 
easily palpable tumor with an approximate diameter of 0.5 cm, we will inject the tumors 
with ecotropic Lenti Orf C virus and appropriate controls (ecotropic Lenti empty vector 
virus or PBS).  The tumors will be injected once every three days, for a total of 21 days.  
Tumors will be imaged at days 7, 14, and 21 with the Xenogen IVIS in vivo imaging 
system and tumor size will be confirmed via calipers as a secondary measure.  On day 21 
animals will be euthanized and tissues collected and analyzed for Orf C expression. 
The importance of moving forward with an in vivo model is several-fold.  First, it 
is important to determine if the Lenti Orf C virus can effectively reduce tumor size.  
Second, we also want to assess if a treatment that results in tumor size reduction is 
associated with an increase in survival time.  Finally, one of the most important aspects 
of conducting an in vivo assessment is to determine if there are any detrimental side 
effects in the use of Lenti Orf C as an oncolytic therapy.  This is especially significant 
since the apoptosis-induced by Orf C is not specific to tumor cells.  Even though it would 
be injected directly into the tumor cells during treatment experiments, it is possible it 
could cause ulcerations or other lesions of the cutaneous tissues that would preclude its 






We have successfully completed our first and second specific AIMS.  We created 
a recombinant lentivirus expressing Orf C and used this Orf C-expressing lentivirus to 
evaluate the in vitro apoptotic potential of Orf C.  We have demonstrated the apoptotic 
properties of our Lenti Orf C virus and specifically identified the MCA-205 mouse tumor 
cell line as a good model for in vitro, and potentially in vivo, experimentation.  We have 
also shown Orf C expression in the nuclear, mitochondrial, and cytosolic cell fractions, 
with the most robust levels of expression in the nuclear cell fraction.   
We have made significant progress on our third AIM of defining the 
mechanism(s) of Orf C-induced apoptosis. We have demonstrated that Orf C appears to 
induce apoptosis via a caspase-independent mechanism.  We have also shown evidence 
that Orf C is associated (perhaps indirectly) with pro-apoptotic proteins ANT and Bax.  
In addition, we have investigated the effect of Orf C on AIF activation. 
Our future study goals are now focused on further characterization of the pro-
apoptotic proteins responsible for inducing cell apoptosis via Orf C.  We would like to 
more extensively characterize the relationship between Orf C and AIF, as well as 
examine an additional pro-apoptotic protein, endonuclease G, that has similar pro-
apoptotic characteristics to AIF.  By characterizing WDSV Orf C-induced apoptosis, we 
can more accurately assess the potential of using Lenti Orf C as an oncolytic therapy.  




move to an in vivo model to assess the potential of Orf C to be used in a clinical 
treatment capacity.  
 In summary, we have made significant discoveries regarding the mechanism of 
Orf C-induced apoptosis.  While there are still questions to be answered regarding the 
unique oncolytic properties of WDSV Orf C, it appears from our initial results that Orf C 
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